CRVO 8-K: SEC filing
CervoMed Inc.
Filed with the SEC on · accession 0001437749-26-037172
CRVO filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
CervoMed Inc. announced the presentation of 24-week interim biomarker data from its ongoing Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA) at the 19th Clinical Trials on Alzheimer's Disease Conference.
Key details
✦ Ask GOAX AI about this filing — what it means for CRVO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CRVO?
Click hereFrequently asked questions
What did CRVO file with the SEC on Nov 16, 2026?
CRVO filed a 8-K (SEC filing). CervoMed Inc. announced the presentation of 24-week interim biomarker data from its ongoing Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA) at the 19th Clinical Trials on Alzheimer's Disease Conference.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other CRVO SEC filings
- 8-K · SEC filingNov 9, 2026
- 10-Q · SEC filingNov 6, 2026
- 8-K · SEC filingOct 29, 2026
- 8-K · SEC filingOct 14, 2026
- 8-K · SEC filingOct 13, 2026
- 8-K · SEC filingOct 9, 2026
- 8-K · Regulatory actionSep 28, 2026
- 8-K · Fda approvalSep 10, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
- SCHEDULE 13G/A · SEC filingAug 14, 2026
Get alerts when CRVO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days